Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc. T.MBX

Alternate Symbol(s):  MBXBF

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.


TSX:MBX - Post by User

Post by Methodon Dec 08, 2020 7:32pm
205 Views
Post# 32063940

Guidance?

Guidance?The results (out last year on Dec 20) could be a big catalyst for a few reasons.

They could put out guidance for F'21 which would put a spotlight on the expected growth next year. Even if it's a wide range.

It might also prompt the analyst at Industrial Alliance to raise her estimates. She's only at $12m in sales and $2m in EBITDA. With the number of people and computers using quant screens, a big jump in analyst estimates could bring in some buying. 


<< Previous
Bullboard Posts
Next >>